

May 19, 2026

Rescheduling Cannabis: The Coming Collision with Ag-Biotech Regulation

Could federal cannabis rescheduling spark the next wave of biotech innovation?

In a recent *mg Magazine* article, Day Pitney Attorneys Jacob Golan, Ph.D., James Leva, and Richard Emmons, Ph.D., explore how moving cannabis to Schedule III could significantly expand cannabis genetics research and accelerate the use of advanced technologies like CRISPR gene editing. They also examine the growing intersection between cannabis regulation and federal oversight of genetically engineered crops as innovation in the industry rapidly evolves.

The piece further highlights the shifting federal oversight landscape for genetically engineered crops and how evolving biotechnology regulations may intersect with cannabis law in the years ahead, potentially reshaping the future of cannabis research, cultivation, and commercialization.

[Read the full article here.](#)

Authors



Jacob Golan, Ph.D.
Associate

Stamford, CT | (203) 977-7320

Boston, MA |

jgolan@daypitney.com



James M. Leva
Partner

Parsippany, NJ | (973) 966-8416

Stamford, CT | (973) 966-8416

jleva@daypitney.com



Richard B. Emmons,
Ph.D.
Partner

Boston, MA | (617) 345-4720

remmons@daypitney.com